ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jan 2024
Last Updated on 02 Jan 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended tafamidis for inclusion on the MOH List of Subsidised Drugs for treating wild-type or hereditary transthyretin amyloid cardiomyopathy. The decision was based on the unfavourable cost-effectiveness of tafamidis at the price proposed by the company, compared with standard management.

Tafamidis for treating transthyretin amyloid cardiomyopathy (Published 2 Jan 2024) PES Tafamidis for treating transthyretin amyloid cardiomyopathy (Published 2 Jan 2024)